A clean redesign helped this clinical-stage biopharmaceutical company, which is developing a next-generation delivery system for botulinum toxin-based prescription products, get off to an impressive start. In January 2016, Anterios was acquired by Allergan, a leading global pharmaceutical company, for $90 million and potential development and commercialization milestone payments. Good design is good business.